DALLAS — Overture Life, the company behind the world’s first babies born through robotic fertilization and robotic egg freezing, has opened its first dedicated U.S. clinical laboratory and operations headquarters in Dallas. Located at 4621 Ross Avenue in The Bogart Building, the facility will serve as the company’s American base for AI-driven fertility innovation.
The new site will conduct non-invasive, CLIA-licensed embryo assessment testing using metabolomic analysis and machine learning to help fertility teams evaluate embryos without the need for biopsies. The Dallas facility will also function as Overture’s central operations hub for U.S. clinical activities.
“This Dallas hub bridges our European manufacturing and research operations with North American markets,” said Hans Gangeskar, CEO of Overture Life. “The central U.S. location facilitates national logistics while giving us access to the biomedical engineering and data science talent concentrated in Texas.”
The Old East Dallas site, near Uptown, will anchor Overture’s U.S. expansion amid growing demand for its DaVitri automated egg-freezing system. The platform uses robotic precision to freeze eggs, achieving a 12 percent improvement in egg survival rates while enabling clinics to triple procedure throughput without adding staff.
Hafsa Irfan, Head of Clinical Operations for the Dallas facility, will oversee the laboratory’s scientific build-out, operations, and optimization of metabolomics assays. “The infrastructure we’re establishing here, from our non-invasive embryo assessment technology to quality systems, creates the foundation for scaling automated fertility care across the United States,” Irfan said.
The facility represents a multi-million-dollar investment in advanced laboratory infrastructure and AI-driven automation. It is designed to expand Overture’s capabilities in non-invasive embryo testing, providing fertility specialists with molecular data to support treatment decisions while avoiding embryo biopsies. The Dallas laboratory will also advance development of Overture’s continuously learning, regulated automation layer—technology that enables reproducible, measurable, and clinically validated AI-assisted IVF procedures.
Dallas was selected for its strong biomedical ecosystem, proximity to research institutions such as UT Southwestern Medical Center, and its growing life sciences workforce. The region employs more than 27,000 professionals across 850 companies, with significant expertise in medical device development and clinical research.
Overture’s automation portfolio targets the most technically demanding procedures in in-vitro fertilization. The company’s ICSI.A system achieved the world’s first births from robotic sperm injection in 2024, while the DaVitri platform standardizes egg freezing, traditionally a process requiring years of manual training. These systems aim to improve consistency and reduce the physical strain on embryologists performing thousands of delicate procedures each year.
The Dallas facility will also serve as a hiring and operations hub, supporting positions across product development, clinical operations, laboratory management, manufacturing, quality assurance, regulatory affairs, and commercial functions. It will coordinate with Overture’s R&D operations in Spain and its expanding global network of clinical partners.
The opening follows strong European demand for the DaVitri system, whose pre-order waitlist filled within weeks of launching in September, as fertility clinics sought proven automation solutions backed by documented healthy births and peer-reviewed outcomes. With the new Dallas headquarters, Overture is positioning itself to scale robotic and AI-assisted fertility care across the United States.
